Fig. 4: NRF2 (NFE2L2) is not required for super-enhancer- and LPS-induced PD-L1 expression.

A Western blot analysis was performed to detect the expression of NRF2 in MCF-7, SUM-159 and MDA-MB-231 cells; B MCF-7, SUM-159 and MDA-MB-231 cells were treated with or without MG132 and the protein level of NRF2 was determined by WB; C Three sgRNAs targeted on NRF2 was stably introduced in SUM-159 and MDA-MB-231 cells. The protein level of NRF2 and PD-L1 was examined in control and NRF2-deficient cells; D Immunofluorescence assays were used to examine the expression of PD-L1 in NRF2-deficient cells; E Representative FACS images to indicate the expression of PD-L1 (PE) and PD-L2 (APC) in NRF2-deficient and control SUM-159 cells. F Summary of the mean fluorescence intensity from (E); G Control and NRF2-deficient SUM-159 cells were treated with LPS at indicated doses. The protein level of PD-L1 in these cells was analyzed by Western blot. H Cells were treated by tBHQ for indicated doses and the protein level of PD-L1 and NRF2 was examined by WB. Data in (A–C and G) are representative of three independent experiments. Data in (D, E and H) are representative of two independent experiments. *p < 0.05; **p < 0.01, ***p < 0.001.